AAllergic rhinitis
First line
Allergic rhinitis
First line
Seasonal and perennial allergic rhinitis in adults and children from 2–3 years (Nasonex from 2). Per ARIA 2020 and SEAIC 2023, intranasal corticosteroids are first-line. Dose: 100–200 µg (2 sprays per nostril) once daily. Effect at 11 hours, full effect at 1–2 weeks. In children 2–11 years, standard dose is 100 µg once daily. Long-term safety on childhood growth confirmed up to 1 year of daily use (Schenkel 2000).
Sources
- AEMPS: Ficha técnica de Mometasona (2024)
- EAACI: ARIA guideline 2019 update on allergic rhinitis (2020)
- BMJ: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. (1998)
- Pediatrics: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. (2000)
ICD-10: J30.9 · ICD-11: CA08.0